¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"lupus inhibitor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • systemic lupus erythematosus
    Àü½ÅÈ«¹Ý·çǪ½º
  • angiotensin converting enzyme inhibitor
    ¾ØÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò¾ïÁ¦Á¦
  • clotting inhibitor
    ÀÀ°í¾ïÁ¦Á¦
  • coagulation factor inhibitor
    ÀÀ°íÀÎÀÚ¾ïÁ¦Á¦
  • competitive inhibitor
    °æÀï¾ïÁ¦Á¦
  • complement inhibitor
    º¸Ã¼¾ïÁ¦Á¦, µµ¿òü¾ïÁ¦Á¦
  • carbonic anhydrase inhibitor
    ź»êÅ»¼öÈ¿¼Ò¾ïÁ¦Á¦
  • converting enzyme inhibitor
    Àüȯȿ¼Ò¾ïÁ¦Á¦
  • corrosion inhibitor
    ºÎ½Ä¾ïÁ¦Á¦
  • enzyme inhibitor
    È¿¼Ò¾ïÁ¦Á¦
  • inhibitor
    1. ¾ïÁ¦Á¦ 2. ¾ïÁ¦ÀÎÀÚ
  • mitotic inhibitor
    À¯»çºÐ¿­¾ïÁ¦Á¦
  • metabolic inhibitor
    ´ë»ç¾ïÁ¦Á¦
  • oocyte maturation inhibitor
    ³­ÀÚ¼º¼÷¾ïÁ¦ÀÎÀÚ
  • polymerization inhibitor
    ÁßÇÕ¾ïÁ¦Á¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • carbonic anhydrase inhibitor
    ź»êÅ»¼öÈ¿¼Ò¾ïÁ¦Á¦
  • clotting inhibitor
    ÀÀ°í¾ïÁ¦Á¦
  • coagulation factor inhibitor
    ÀÀ°íÀÎÀÚ¾ïÁ¦Á¦
  • competitive inhibitor
    °æÀï¾ïÁ¦Á¦
  • complement inhibitor
    º¸Ã¼¾ïÁ¦Á¦, µµ¿òü¾ïÁ¦Á¦
  • converting enzyme inhibitor
    Àüȯȿ¼Ò¾ïÁ¦Á¦
  • corrosion inhibitor
    ºÎ½Ä¾ïÁ¦Á¦
  • enzyme inhibitor
    È¿¼Ò¾ïÁ¦Á¦
  • inhibitor
    ¾ïÁ¦Á¦
  • inhibitor substance
    ¾ïÁ¦¹°Áú
  • metabolic inhibitor
    ´ë»ç¾ïÁ¦Á¦
  • mitotic inhibitor
    Çٺп­¾ïÁ¦Á¦
  • oocyte maturation inhibitor
    ³­ÀÚ¼º¼÷¾ïÁ¦ÀÎÀÚ
  • particle-enhanced turbidimetric inhibitor
    ÀÔÀÚÁõ´ëȥʾïÁ¦Á¦
  • polymerization inhibitor
    ÁßÇÕ¾ïÁ¦Á¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • angiotensin converting enzyme inhibitor
    ¾ÈÁö¿ÀÅٽŠÀüȯȿ¼Ò ¾ïÁ¦¹°Áú<¾à>.
  • anti-inhibitor coagulation complex
    Ç×¾ïÁ¦Á¦ÀÀ°í°áÇÕü
  • growth inhibitor
    ¼ºÀå<¹ßÀ°>¾ïÁ¦¹°Áú.
  • inhibitor
    ¾ïÁ¦Á¦
  • inhibitor
    ÀúÁöÀÚ, ¾ïÁ¦ÀÚ, ¾ïÁ¦ÀÎÀÚ
  • inhibitor
    ¾ïÁ¦ÀÚ
  • inhibitor polymerization
    ÁßÇÕ¾ïÁ¦Á¦.
  • inhibitor sensitive esterase
    ¾ïÁ¦¹°Áú¹ÝÀÀ¿¡½ºÅ×¶ó¾ÆÁ¦.
  • inter-alpha-trypsin inhibitor
    ÀÎÅÍ-¾ËÆÄ-Æ®¸³½Å ¾ïÁ¦Á¦
  • plasma thromboplastin inhibitor
    ÇöóÁ <Ç÷Àå>Æ®·Òº¸ÇÃ¶ó½ºÆ¾¾ïÁ¦¹°Áú.
  • plasmin activation inhibitor
    Çö󽺹ÎȰ¼ºÈ­¾ïÁ¦Á¦(¡­üÀàõûùåäð¤ð¥)
  • protease inhibitor
    ´Ü¹éÁúºÐÇØÈ¿¼Ò¾ïÁ¦Á¦
  • reductase, 5-alpha-reductase inhibitor
    5a-ȯ¿øÈ¿¼Ò¾ïÁ¦Á¦(¡­ü½êªý£áÈåäð¤ð¥),5a-¸®´öÅ×À̽º¾ïÁ¦Á¦(¡­åäð¤ð¥)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • complement inhibitor
    º¸Ã¼ÀúÁöÀÎÀÚ.
  • complement inhibitor
    º¸Ã¼ÀúÁöÀÎÀÚ.
  • complement inhibitor
    º¸Ã¼ÀúÁöÀÎÀÚ.
  • converting enzyme inhibitor
    Àüȯȿ¼Ò¾ïÁ¦Á¦.
  • corrosion inhibitor
    ºÎ½Ä¹æÁöÁ¦(¡­ÛÁò­ð¥).
  • enzyme inhibitor
    È¿¼ÒÀúÇØÁ¦.
  • fertility inhibitor
    ¼öÁ¤¾ïÁ¦Á¦.
  • growth inhibitor
    ¼ºÀå<¹ßÀ°>¾ïÁ¦¹°Áú.
  • inhibitor
    ¾ïÁ¦Á¦
  • inhibitor
    ¾ïÁ¦ÀÚ
  • inhibitor
    ÀúÁöÀÚ, ¾ïÁ¦ÀÚ, ¾ïÁ¦ÀÎÀÚ
  • inhibitor polymerization
    ÁßÇÕ¾ïÁ¦Á¦.
  • inhibitor sensitive esterase
    ¾ïÁ¦¹°Áú¹ÝÀÀ¿¡½ºÅ×¶ó¾ÆÁ¦.
  • insulinase inhibitor
    Àν¶¸®³ª¾ÆÁ¦ÀúÇØ¹°Áú, Àν¶¸°ºÐÇØÈ¿¼Ò¾ïÁ¦¹°Áú.
  • inter-alpha-trypsin inhibitor
    ÀÎÅÍ-¾ËÆÄ-Æ®¸³½Å ¾ïÁ¦Á¦
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • transition state inhibitor
    õÀÌ»óÅ ÀúÇØÁ¦(ôÃì¹ßÒ÷¾îÁúªð¥)
  • Trojan horse inhibitor
    Æ®·ÎÀ̸ñ¸¶(ÙÊØ©) ÀúÇØÁ¦(îÁúªð¥)
  • uncompetitive inhibitor
    ¹«°æÇÕ(ÙíÌæùê) ÀúÇØÁ¦(îÁúªð¥)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
STI Scientific and Technical Information; serum trypsin inhibitor; soybean trypsin inhibitor; systolic t...
DLE Discoid Lupus Erythematosus
LE Lupus Erythematosus; È«¹Ý¼º ·çǪ½º(³¶Ã¢)
SCLE Subacute Cutaneous Lupus Erythematosus
SLE Systemic Lupus Erythematosus; Àü½Å¼º È«¹Ý¼º ·çǪ½º(³¶Ã¢)(îïãóàõ ûõÚèàõ)
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LA lupus anticoagulans
LE Lupus Erythematosus
LN Lupus Nephritis
LBT Lupus band test
NLE Neonatal lupus erythematosus
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • drug-induced lupus
    ¾à¹° À¯¹ß ·çǪ½º
  • lupus
    ·çǪ½º, ³¶Ã¢
    óÀ½¿¡´Â ÆÄ±«¼º ÇǺΠº´º¯¿¡ ºÙÀÎ ¸íĪÀ¸·Î °©»ó¼±Á¾¿¡ À¯·¡Çϰí, ¸¸¼ºÀÌ¸ç ºñ´ë, Èí¼ö, ±Ë¾ç µîÀ» µ¿¹ÝÇÏ´Â ±¹¼Ò º´º¯.
  • lupus discoid erythematosus
    ¿øÆÇ»ó È«¹Ý¼º ·çǪ½º
  • lupus erythematosus cell
    È«¹Ý¼º ·çǪ½º ¼¼Æ÷, È«¹Ý¼º ³¶Ã¢ ¼¼Æ÷
  • lupus erythematosus like syndrome
    È«¹Ý¼º ·çǪ½º¾ç ÁõÈıº
  • lupus erythematosus visceralis
    È«¹Ý¼º ³»À强 ³¶Ã¢
  • lupus hypertrophicus
    ºñÈļº ·çǪ½º
  • lupus nephritis
    ³¶Ã¢¼º ½ÅÀå¿°
  • lupus vulagris
    ½É»ó¼º ³¶Ã¢, ½É»ó¼º ·çǪ½º, º¸Åë ·çǪ½º
    ÇǺÎÀÇ ¿ø¹ß¼º °áÇÙÀ¸·Î ±«¾ç¼ºÀÇ ±¸Áø¼º ¼Ò°áÀýÀ» º¸ÀÌ¸ç Æ¯È÷ ¾ó±¼¿¡ Àß ¹ß»ýÇÑ´Ù.
  • lupus-like syndrome
    ³¶Ã¢ ¾ç»óÀÇ ÁõÈıº
  • serum lupus erythematosus
    Ç÷û È«¹Ý¼º ³¶Ã¢
  • system lupus erythematosus
    Àü½Å¼º È«¹Ý¼º ³¶Ã¢
  • systemic lupus erythematosus
    Àü½Å¼º È«¹Ý¼º ³¶Ã¢, Àü½Å¼º È«¹Ý¼º ·çǪ½º
    1. °üÀý, ÇǺΠ±âŸ ³»Àå µî Àü½ÅÀûÀ¸·Î ħ¹üÇÏ´Â ÀÚ°¡ ¸é¿ª¼º ¿°Áõ¼º Áúȯ. 2. ÁÖ·Î Áß³âÀÇ ¿©¼º¿¡¼­ ¹ßº´ÇÏ´Â Àü½Å¼º °áÇÕ Á¶Á÷ Àå¾Ö·Î¼­ ÇǺΠº´¼Ò, Ç÷°ü¿°, °üÀýÅë, ±×¸®°í ¹éÇ÷±¸ °¨¼ÒÁõÀÇ ¿øÀÎÀÌ µÈ´Ù. º¸Åë Ç×ÇÙ Ç×ü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
lupus erythematodes Skin disease in which there are red scaly patches, especially over the nose and cheeks. May be a symptom of systemic lupus erythematosus.
(18 Nov 1997)
lupus erythematosus Skin disease in which there are red scaly patches, especially over the nose and cheeks. May be a symptom of systemic lupus erythematosus.
(18 Nov 1997)
lupus erythematosus cell <pathology> Phagocyte that has ingested nuclear material of another cell: characteristic of systemic lupus erythematosus.
(18 Nov 1997)
lupus erythematosus cell test <investigation> A test for lupus that measures the presence of autoantibodies against nuclear proteins in the blood. Performed on a normal venipuncture specimen, this test is positive in 70 to 80% of patients with lupus. Some patients with rheumatoid arthritis, scleroderma and drug-induced lupus may also have a positive test result.
(27 Sep 1997)
lupus erythematosus, cutaneous A form of lupus erythematosus in which the skin may be the only organ involved or in which skin involvement precedes the spread into other body systems. It has been classified into three forms - acute (= lupus erythematosus, systemic with skin lesions), subacute, and chronic (= lupus erythematosus, discoid).
(12 Dec 1998)
lupus erythematosus, discoid A chronic form of cutaneous lupus erythematosus (lupus erythematosus, cutaneous) in which the skin lesions mimic those of the systemic form but in which systemic signs are rare. It is characterised by the presence of discoid skin plaques showing varying degrees of oedema, erythema, scaliness, follicular plugging, and skin atrophy. Lesions are surrounded by an elevated erythematous border. The condition typically involves the face and scalp, but widespread dissemination may occur.
(12 Dec 1998)
lupus erythematosus profundus A subcutaneous panniculitis with marked lymphocyte infiltration of fat lobules giving rise to deep-seated, firm, rubbery nodules that sometimes become ulcerated, usually of the face; may occur in systemic and localised lupus erythematosus.
Synonym: lupus profundus.
(05 Mar 2000)
lupus erythematosus, systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterised principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown aetiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of le cells in the blood or bone marrow.
(12 Dec 1998)
lupus erythematosus test <investigation> A test for lupus that measures the presence of autoantibodies against nuclear proteins in the blood. Performed on a normal venipuncture specimen, this test is positive in 70 to 80% of patients with lupus. Some patients with rheumatoid arthritis, scleroderma and drug-induced lupus may also have a positive test result.
(27 Sep 1997)
lupus glomerulonephritis-pathology Patient survival and preservation of renal function are predictable from renal pathology as demonstrated by biopsy and defined by the histological classification of the International Study of Kidney Disease in Children/World Health Organization (ISKDC/WHO). Semi-quantitative indices of nephron loss (chronicity index) and activity of acute potentially reversible inflammation (activity index) are not predictive of individual outcome, renal failure or death in patients with aggressively treated SLE GN.
(05 Mar 2000)
lupus-like syndrome <syndrome> A clinical syndrome resembling that of systemic lupus erythematosus, but due to some other cause.
(05 Mar 2000)
lupus livido Persistent cyanotic lesions on the extremities, associated with the cutaneous manifestations of Raynaud's disease.
(05 Mar 2000)
lupus lymphaticus A congenital nevoid lesion consisting of a circumscribed group of tense lymph vesicles.
Synonym: lupus lymphaticus, lymphangiectodes, lymphangioma capillare varicosum, lymphangioma superficium simplex.
(05 Mar 2000)
lupus miliaris disseminatus faciei A millet-like papular eruption of the face, associated with a (histopathologically) tuberculoid perifollicular infiltration, but probably related to rosacea rather than tuberculous infection.
(05 Mar 2000)
lupus mutilans Cutaneous tuberculosis with extensive destruction of tissue.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á